Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. engages in the development, manufacturing and marketing of prescribed and over-the-counter pharmaceutical products in the U.S., Canada and Israel. Its products include semi-solids formulations, such as creams and ointments and other dosage forms such as liquids, capsules and tablets, in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The company was founded in 1950 and is headquartered in Haifa Bay, Israel.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR THE QUARTER ENDED JUNE 30, 2023.

Taro Provides Results for the Quarter Ended June 30, 2023

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO TO RELEASE FIRST QUARTER RESULTS ON JULY 26, 2023.

Taro to Release First Quarter Results on July 26, 2023

NEW YORK , July 19, 2023 /PRNewswire/ -- As the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), Krensavage Asset Management LLC opposes Sun Pharmaceutical Industries Ltd.

Krensavage Asset Management Opposes Sun's Lowball Bid for Taro

Taro received a $38/share offer from Sun Pharma last month. The deal represents a decent premium to the firm's market value at the time and a 12% premium to my estimate of fair value. Further insights reveal the deal could be valuable to Taro shareholders given all the contributing factors.

Taro Pharmaceutical: Potential Value In Sun Pharma Offer

Taro saw rising revenue in the fourth quarter but falling net income. Sun Pharmaceutical already owns 78.5% of Taro's shares.

Why Shares of Taro Pharmaceutical Are Rising Tuesday

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and year ended March 31, 2023. Quarter ended March 31, 2023* Highlights ─ compared to March 31, 2022 Net sales of $146.6 million increased $3.3 million, or 2.3%. Gross profit of $75.7 million (51.6% of net sales) compared to $77.3 million (54.0% of net sales). Research and development (R&D) expenses of $16.3 million increased.

Taro Provides Results for Year Ended March 31, 2023

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the year ended March 31, 2023, after the close of market on Tuesday, May 23, 2023. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturi.

Taro to Release Full Year Results on May 23, 2023

Taro Pharmaceutical's quarterly numbers came in with very thin growth at the operating and bottom-lines given the impact from settlement charges. Price erosion in its U.S. generics business continues to be a headwind.

Taro Pharmaceutical: Stagnating Growth At 1.6% Trailing Earnings Yield, Rate Hold

Energy Transfer LP Unit

Fresenius Medical Care

Organon & Co

Teva Pharmaceutical

Viatris

Francisco Garcia Parames' Cobas Funds 4th-Quater Letter

Taro (TARO) delivered earnings and revenue surprises of -78.16% and 14.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (TARO) Lags Q3 Earnings and Revenue Estimates

HAWTHORNE, N.Y.--( BUSINESS WIRE )--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2022.

Taro Provides Results for December 31, 2022

HAWTHORNE, N.Y.--( BUSINESS WIRE )--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2022, after the close of market on Tuesday, January 24, 2023.

Taro to Release Third Quarter Results on January 24, 2023

Taro (TARO) delivered earnings and revenue surprises of -108.33% and 18.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (TARO) Reports Q2 Loss, Misses Revenue Estimates

Taro Provides Results for September 30, 2022

Taro to Release Second Quarter Results on October 27, 2022

BRAMPTON, Ontario--(BUSINESS WIRE)--TARO PHARMACEUTICALS INC. ISSUES VOLUNTARY TYPE I RECALL OF TARO-ZOLEDRONIC ACID INJECTION, 5 MG/100 ML, 100 ML VIAL

Taro Pharmaceuticals Inc. Issues Voluntary Type I Recall of Taro-Zoledronic Acid Injection, 5 mg/100 mL, 100 mL Vial Due to Particulate Matter Over Specified Requirements

Taro (TARO) delivered earnings and revenue surprises of -56.47% and 4.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Taro Pharmaceutical (TARO) Lags Q1 Earnings Estimates

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR THE QUARTER ENDED JUNE 30, 2022

Taro Provides Results for the Quarter Ended June 30, 2022

HAWTHORNE, N.Y.--(BUSINESS WIRE)--07-26-22 March 2022 Annual Report on Form 20-F

Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2022

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the first quarter ended June 30, 2022, after the close of market on Wednesday, July 27, 2022. The release will be accessible on Taro's website at www.taro.com. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development,

Taro to Release First Quarter Results on July 27, 2022

Based on the current long-term trend, shares look like they will test long-term support. We expect support to hold there based on the company's strong earnings power and clean balance sheet.

Taro Pharmaceutical: 10%+ Projected Earnings Yield Is A Strong Calling Card

HAWTHORNE, N.Y.--(BUSINESS WIRE)--TARO PROVIDES RESULTS FOR THE YEAR ENDED MARCH 31, 2022

Taro Provides Results for the Year Ended March 31, 2022

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro to Announce Full Year Results on May 27, 2022

Taro to Announce Full Year Results on May 26, 2022

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Completes Acquisition of Alchemee

Taro Completes Acquisition of Alchemee

ZUG, Switzerland & HAWTHORNE, N.Y.--(BUSINESS WIRE)--Galderma and Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro”) announced today they have signed a definitive agreement for Taro to acquire Alchemee, formerly The Proactiv Company (TPC), from Galderma. The agreement between Galderma and Taro includes Alchemee's business and assets around the world, including the Proactiv® brand.   "We are excited to add Proactiv® to Taro's broad portfolio of prescription and over-the- counter dermatolo

News for Taro Pharmaceutical Industries Stock (TARO)